Sequoia Vaccines, Inc.
PrivateLast Round
IPO
May 5, 2025
Est. Valuation
$80M
Total Funding Raised
$34.5M
Company Overview
Sequoia Vaccines, Inc. operates in Healthcare & Life Sciences and is based in St. Louis, Missouri. Its latest recorded funding round was a Convertible Debt round in October 2023.
Sequoia Vaccines, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of novel vaccines to prevent bacterial infections and small-molecule therapeutics for the treatment of cancers and lung infections.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sequoia Vaccines, Inc. Comparables
Compare Sequoia Vaccines, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Fimbrion Therapeutics | 79% | |
| Locus Biosciences | 74% | |
| Inmunotek | 73% |
For institutional investors. Book with your work email.
Sequoia Vaccines, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | May 5, 2025 | ||||
| Convertible Debt | Oct 1, 2023 | ||||
| Series B | Mar 1, 2021 | ||||
| Convertible Debt | Dec 1, 2019 | ||||
| Grant | Sep 1, 2014 | ||||
Series A | Jan 1, 2013 |
For institutional investors. Book with your work email.
Sequoia Vaccines, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Holton Capital Group | Series A |
| NIH RADx | Grant |
| Cultivation Capital | Series A |
| St. Louis Arch Angels | Series A |
| Prolog Ventures | Convertible Debt, Series A |
| ThinkEquity | IPO |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 1, 2023
$4M raised with participation from Prolog Ventures.
- Mar 1, 2021
$5M round completed.
For institutional investors. Book with your work email.
Sequoia Vaccines, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Sequoia Vaccines, Inc.'s valuation, stock price, and market status.
Is Sequoia Vaccines, Inc. a public or private company?
Sequoia Vaccines, Inc. is a private company.
What is the current stock price of Sequoia Vaccines, Inc.?
Sequoia Vaccines, Inc. is a private company, so its shares have no public market price. Caplight tracks Sequoia Vaccines, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Sequoia Vaccines, Inc. worth (valuation)?
Sequoia Vaccines, Inc.'s valuation is estimated at $80.0M based on funding round data.
Can I buy Sequoia Vaccines, Inc. stock?
Sequoia Vaccines, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Sequoia Vaccines, Inc.'s last funding round?
Sequoia Vaccines, Inc.'s most recent funding round was IPO on May 5, 2025.
Who are the main investors in Sequoia Vaccines, Inc.?
Key investors in Sequoia Vaccines, Inc. include ThinkEquity.
Will Sequoia Vaccines, Inc. IPO soon?
No public IPO plans have been announced for Sequoia Vaccines, Inc..
How can I track Sequoia Vaccines, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Sequoia Vaccines, Inc.'s shares on secondary markets.